

PATENT COOPERATION TREATY

30

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:
RANBAXY LABORATORIES LIMITED
C/O DESHMUKH, JAYADEEP R.
600 COLLEGE ROAD EAST, SUITE 2100
PRINECTON, NJ 08540

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing
(day/month/year)

08 JUL 2004

Applicant's or agent's file reference

RLL-236WO

IMPORTANT NOTIFICATION

International application No.

PCT/IB02/01113

International filing date (day/month/year)

11 April 2002 (11.04.2002)

Priority date (day/month/year)

Applicant

RANBAXY LABORATORIES LIMITED

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US

Mail Stop PCT, Attn: IPEA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 872-9306

Authorized officer

Emily Bernhardt

Telephone No. (571) 272-1600

F. Roberts for

Form PCT/IPEA/416 (July 1992)



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference RLL-236WO	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/IB02/01113	International filing date (<i>day/month/year</i>) 11 April 2002 (11.04.2002)	Priority date (<i>day/month/year</i>)
International Patent Classification (IPC) or national classification and IPC IPC(7): C07D 209/48, 401/06, 403/06, 491/08; A61K31/4035, 31/496. and US Cl.: 544/360,372,373; 548/465, 513; 514/253.12, 254.08,414, 421.		
Applicant RANBAXY LABORATORIES LIMITED		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>4</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of <u>0</u> sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input checked="" type="checkbox"/> Non-establishment of report with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application 		
Date of submission of the demand 05 November 2003 (05.11.2003)	Date of completion of this report 28 June 2004 (28.06.2004)	
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 872-9306	Authorized officer Emily Bernhardt <i>F. Robert Gior</i> Telephone No. (571) 272-1600	

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/IB02/01113

I. Basis of the report**1. With regard to the elements of the international application:***

- ☒ the international application as originally filed.
- ☒ the description:
pages 1-45 _____ as originally filed
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____.
- ☒ the claims:
pages 46-80 _____, as originally filed
pages NONE _____, as amended (together with any statement) under Article 19
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____.
- ☒ the drawings:
pages NONE _____, as originally filed
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____.
- ☐ the sequence listing part of the description:
pages NONE _____, as originally filed
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.These elements were available or furnished to this Authority in the following language English which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages NONE
- ☐ the claims, Nos. NONE
- ☐ the drawings, sheets/fig NONE

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/IB02/01113

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The question whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- ☐ the entire international application,
☒ claims Nos. 1, 3-36 (all in part)

because:

- ☐ the said international application, or the said claim Nos. _____ relate to the following subject matter which does not require international preliminary examination (*specify*):

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____ are so unclear that no meaningful opinion could be formed (*specify*):

- ☐ the claims, or said claims Nos. _____ are so inadequately supported by the description that no meaningful opinion could be formed.

- ☒ no international search report has been established for said claims Nos. 1, 3-36 (all in part)

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/IB02/01113**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)	Claims 16-36	YES
	Claims 1-15	NO
Inventive Step (IS)	Claims 16-36	YES
	Claims 1-15	NO
Industrial Applicability (IA)	Claims 1-36	YES
	Claims NONE	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-15 lack novelty and thus an inventive step under PCT Article 33(2)-(3) as being anticipated and rendered obvious by Ranbaxy (WO'206). The WO publication describes many compounds for use as alpha A1 adrenergic antagonistic activity as well as processes for making. See pages 5-12 for list of compounds and pages 15-26 for processes outlined in claims 8-12.

Claims 1,2,5,6 and 13 lack novelty and thus an inventive step under PCT Article 33(2)-(3) as being anticipated and thus rendered obvious by Hirose (US'954). The US patent describes similar and identical compounds to that claimed herein for treating diabetes. See columns 1-5 and column 24, lines 1-10. Process of claim 13 is employed to make said compounds as discussed in columns 3-4.

Claims 14-15 lack an inventive step under PCT Article 33(3) as being obvious over Hirose in view of Ishizumi (US'117). While the reaction conditions set forth in 14 and 15 are not particularly exemplified in Hirose, Hirose teaches ethanol among other solvents to run the reaction as set forth in column 4. Ishizumi teaches for related compounds prepared by the same process use of base including carbonates embraced in claim 15. See columns 3-4.

Claims 16-36 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the reaction steps outlined in the process claims to make particular products recited therein.

Claims 1-36 meet the criteria set out in PCT Article 33(4), and thus possess industrial applicability because the subject matter claimed can be made or used in industry. Compounds are taught for treating benign prostatic hyperplasia.